Intuniv - Honik LLC
16016
post-template-default,single,single-post,postid-16016,single-format-standard,bridge-core-2.8.5,qode-page-transition-enabled,ajax_fade,page_not_loaded,,side_area_uncovered_from_content,qode-child-theme-ver-1.0.0,qode-theme-ver-26.9,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.6.0,vc_responsive
 

Intuniv

Intuniv

Intuniv is a popular brand-name drug to treat ADHD, particularly for pediatric patients.  Rather than face generic competition, the brand manufacturer of Intuniv entered into a so-called “pay for delay” agreement with the lead generic manufacturer to delay a generic version of Intuniv.  This resulted in consumers paying higher branded-drug prices for a longer period of time than they should have.  Ruben Honik is co-lead counsel leading the plaintiff group representing consumers in multiple states seeking to hold the manufacturers accountable under the antitrust and other laws for engaging in this “pay for delay” scheme.